Holen Sie sich die Stockscreener-App
172.34
2.82%
-5.00
Handel nachbörslich:
172.41
0.07
+0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology - The Chronicle-Journal
Biogen : to Report First Quarter 2026 Financial Results April 29, 2026 - marketscreener.com
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.
Revisiting Eisai And Biogen's Leqembi Data For Alzheimer's Disease (NASDAQ:BIIB) - Seeking Alpha
Biogen Paid a 140% Premium for Apellis. Was the $5.6B Deal Worth It? - TIKR.com
Biogen Expects to Take $0.19 per Share Charge in Q1 - marketscreener.com
Biogen Inc. 8-K SEC Filing Details for April 6, 2026: Company Information, Stock, and Compliance Overview - Minichart
Biogen expects $34 million charge for research and development expenses By Investing.com - Investing.com India
Biogen expects $34 million charge for research and development expenses - Investing.com
Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get - Benzinga
Biogen (NASDAQ: BIIB) projects $34M Q1 2026 in-process R&D expense - Stock Titan
Biogen Inc. (BIIB) stock price, news, quote and history - Yahoo Finance Singapore
Biogen Inc. (BIIBCL.SN) interactive stock chart - Yahoo Finance UK
Apellis Pharmaceuticals (APLS) hits 2-year high on 140% upside from Biogen merger - MSN
BIIB (Biogen) 3-Year Revenue Growth Rate : -1.20% (As of Dec. 2025) - GuruFocus
Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation Story - Yahoo Finance Singapore
Stifel Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $214 - Moomoo
15,051 Shares in Biogen Inc. $BIIB Bought by Element Squared LLC - MarketBeat
Biogen (NASDAQ: BIIB) plans tender offer to acquire Apellis (APLS); materials pending - Stock Titan
Biogen (BIIB) CAO Sean Godbout nets shares from RSU vesting and tax withholding - Stock Titan
Biogen to acquire Apellis in $5.6 billion deal - Ophthalmology Times
Biogen Inc stock: Plunges to $177.34 – What it means for you - AD HOC NEWS
Rx Rundown: Eli Lilly, Blackstone, Biogen and more - Medical Marketing and Media
Nisa Investment Advisors LLC Sells 9,121 Shares of Biogen Inc. $BIIB - marketbeat.com
Biogen Inc. stock underperforms Thursday when compared to competitors - MSN
Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS - RTTNews
Biogen Inc. (BIIB) Stock Forecasts - Yahoo Finance
APLS Stock Soars 140% Today – Here’s Everything To Know About Apellis' Massive $5.6B Deal With Biogen - Stocktwits
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - Yahoo Finance
Biogen (NASDAQ:BIIB) Target Revision Sparks Nasdaq Futures Focus - Kalkine Media
Why Biogen Is Paying $5.6B to Buy Apellis Pharma - MedCity News
List of 13 Acquisitions by Biogen (Apr 2026) - Tracxn
H.C. Wainwright raises Biogen stock price target on Apellis deal By Investing.com - Investing.com India
H.C. Wainwright raises Biogen stock price target on Apellis deal - Investing.com
BIIB Analyst Rating: HC Wainwright & Co. Raises Price Target to $237 | BIIB Stock News - GuruFocus
Biogen’s $5.6 Billion Apellis Buy Drives Top Trading Volume Amid Share Price Slide - Bitget
BIIB Stock Price, Quote & Chart | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Biogen Acquires Apellis for $5.6B, Shares Dip | Strategic Immunology MoveNews and Statistics - IndexBox
Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets - BioPharma Dive
Canaccord Genuity Raises Price Target for Biogen (BIIB) to $245 - gurufocus.com
Mass. companies close major deals in biotech, media in March - The Business Journals
Biogen Inc (BSP:BIIB34) Stock Price, Trades & News - gurufocus.com
Oppenheimer Raises Biogen (BIIB) Price Target to $275, Maintains Outperform Rating | BIIB Stock News - GuruFocus
FDA Approves Higher-Dose Regimen of Nusinersen for Spinal Muscular Atrophy - Pharmacy Times
Biogen’s $5.6bn Apellis Deal Delivers Windfall for Worldwide Healthcare Trust - TipRanks
Biogen to acquire Apellis Pharmaceuticals for $5.6 billion - Investing.com
Biogen to acquire Apellis Pharmaceuticals for $5.6 billion By Investing.com - Investing.com India
Biogen stock is locked into a rising trendline — And $202.41 is the destination - fxstreet.com
Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals - Pharmaceutical Executive
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio - Yahoo Finance
Biogen (NASDAQ:BIIB) Price Target Raised to $191.00 - marketbeat.com
Biogen (NASDAQ:BIIB) Given New $275.00 Price Target at Oppenheimer - marketbeat.com
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes - BioSpace
Biogen (NASDAQ:BIIB) Price Target Raised to $245.00 at Canaccord Genuity Group - marketbeat.com
Biogen Inc. stock outperforms competitors on strong trading day - MSN
Canaccord Genuity Adjusts Biogen PT to $245 From $230, Maintains Buy Rating - MarketScreener
Oppenheimer Adjusts Price Target on Biogen to $275 From $250, Maintains Outperform Rating - marketscreener.com
Biogen stock price target raised to $245 by Canaccord on Apellis deal - Investing.com
Wedbush Raises Price Target on Biogen to $191 From $187, Keeps Neutral Rating - marketscreener.com
Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout - Yahoo Finance
Apellis Pharmaceuticals to be Acquired by Biogen in Merger - TipRanks
Biogen bolsters immunology offerings with $5.6bn Apellis buy - bioxconomy.com
Apellis Pharmaceuticals (APLS) Hits 2-Year High on 140% Upside from Biogen Merger - Yahoo Finance
Biogen to Acquire Apellis, Expanding Ophthalmology Portfolio - TipRanks
Why Biogen Stock Sank While the Market Soared on Thursday - Yahoo Finance
1.73%
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):